Leukemia Clinical Trials in Arizona

Showing 901-920 of 1,229 trials

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00436618

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or not responded to previous treatment.

LeukemiaLymphomaLymphoproliferative Disorder

Mayo Clinic277 participantsStarted Aug 2005

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 231 miles

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02666950

This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving WEE1 inhibitor AZD1775 works better with or without cytarabine in treating patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Isolated Del(5q)Myelodysplastic/Myeloproliferative Neoplasm+3 more

Mayo Clinic3 participantsStarted May 2017

Scottsdale, Arizona, United States

No Longer Available31 miles

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NCT02312037

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com

CD33 Positive Acute Myelogenous Leukemia

Pfizer

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +139 more locations

PreviousPage 46 of 62Next

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Leukemia Trials in Other Cities

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Study LY2228820 for Recurrent Ovarian Cancer

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Registry for Integrative Medicine Interventions Effectiveness

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery

Study of Ramucirumab in Ovarian Cancer

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

A Study in Non-Small Cell Lung Cancer

Other Conditions in Arizona